Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study for the Evaluation of Clinical Effectiveness in Routine Practice of Daxas® (Roflumilast), in Approximately 2700 Patients With Severe and Very Severe COPD (Chronic Obstructive Pulmonary Disease) in Greece

NCT02187926 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02187926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study for the Evaluation of Clinical Effectiveness in Routine Practice of Daxas® (Roflumilast), in Approximately 2700 Patients With Severe and Very Severe COPD (Chronic Obstructive Pulmonary Disease) in Greece
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2013
Enrollment
2,577 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease